Mar 22 (1 day ago)
Joaquín Rodrigo Garza Pérez <rgarza@ciencias.unam.mx>

http://redoctober.sisal.unam.mx/1CPAC/Panamerican_Coral_Reef_Congress/Resumenes___Abstracts.html

http://redoctober.sisal.unam.mx/1CPAC/Panamerican_Coral_Reef_Congress/Merida_2013.html

Dear Colleagues:

New information on the congress venue, official hotel, registry fees and airfare discounts is available at the Congress website! See you in Mérida!

Greetings from the Local Organizing Committee

ES

Estimados Colegas:

Ya está disponible la información de la sede del congreso, el hotel
oficial, las cuotas de inscripción y descuento en boletos de avión, en el
sitio web del Congreso.

Nos vemos en Mérida!

Saludos cordiales de parte del Comité Organizador Local

Página de Registro

 

ES

 

1. *Los resúmenes deberán ser enviados a través del sistema de envío de resúmenes en el portal web del congreso.

 

1. *Para accesar este sistema de envío de resúmenes el autor principal deberá darse de alta en el sistema.

 

1. *Se deberá escoger la modalidad en la que se desea presentar (oral ó póster)

 

1. *Se deberá escoger el tema de las sesiones en donde el resúmen sea más adecuado

Los temas podrán ser consultados en la página: Sesiones del Congreso

 

1. *Los resúmenes para presentaciones orales y pósters deberán ser enviados para su revisión y eventual aprobación tanto en Español como en Inglés (Incluyendo títulos y cuerpo del resumen).

 

1. *Cada versión del resumen podrá tener una extensión máxima de 2,200 caracteres.

 

1. *No se deben incluir citas en los resúmenes

 

1. *NOTA IMPORTANTE: Los resúmenes y sus títulos deben ser escritos y modificados en un programa de editor de texto. Cuando se cuente con su versión final deberán ser copiados desde el documento y pegados en los campos apropiados en el sistema de envío. Una vez envíado el resumen, este no podrá ser modificado en el sistema.

 

Preguntas y comentarios: panamcoralreefs@outlook.com

Registry Page

 

EN

 

1. *Abstracts must be submitted using the Online Abstract Submission Form in the Congress’ Website.

 

1. *In order to access this system, corresponding authors must register on the system.

 

1. *A modality for presentation must be chosen.

 

1. *A theme session were the abstract could be most relevant must be chosen.

Theme sessions can be consulted on the congress sessions page

 

1. *Abstracts for oral presentations and posters will be accepted in Spanish with its mandatory translation in English (or viceversa), both for titles and body of the abstract.

 

1. *Each abstract version might have a maximum length of 2,200 characters.

 

1. *No references should be included on the abstracts.

 

1. *IMPORTANT: Abstracts and titles must be written and modified in a text editing software. When you have your final version, you must copy from the document and paste on the appropriate fields of the abstract submission form. Once submitted the abstract cannot be modified on the system.

 

 

Question or Comments: panamcoralreefs@outlook.com

7th Mexican &

1st Pan-American

Coral Reef Congress

Perspectivas Arrecifales: Manejo Local, Impactos Globales

 

Reef Perspectives: Local Management, Global Impacts

Days

Hours

Mins

Secs

Abstracts Reception Period Ends In:

El Período de Recepción de Resúmenes Termina en:

Costo de Inscripción / Registry Fees

INTERNACIONAL / INTERNATIONAL

ON-LINE EARLY-BIRD (Abril / April – Julio/July, 2013)

Profesores / Professors   $200.00 USD

Estudiantes / Students  $100.00 USD

ON-LINE (Agosto / August – Septiembre / September, 2013)

Profesores / Professors   $220.00 USD

Estudiantes / Students  $110.00 USD

NACIONAL (EN MÉXICO / WITHIN MÉXICO )

Depósito a Cuenta BBVA Bancomer

(Abril a Septiembre)

Profesores   $2,400.00 MXP

Estudiantes   $1,200.00 MXP

En la Puerta / At The Door (Oct. 7-11, 2013)

Profesores / Professors  $2,800.00 MXP

Estudiantes / Students  $1,400.00 MXP

Ok, this isn’t about the ocean or coral reefs but it is an issue that is near and dear to my heart.    My husband was cured of Hepatitis C in a Phase 2 clinical trial involving two medicines owned by two different companies. They achieved an astounding 100% cure rate in all patients with little to no side effects.   One of the pills was sold to Gilead Sciences, that now refuses to go to Phase 3 trials, FDA approval and to market with the drugs.

I’m working with HCV: Coalition for the Cure  to help get the cure out.  Hep C now kills 1000 people a day in America–exceeding that of AIDS.  Please sign our White House petition seeking the President’s involvement in urging the release of this important way to save lives.  Go to http://www.hepc-cured.org  and sign today. You’ll have to register but it’s worth it.

Many thanks,   DeeVon    ps here’s our press release:

According to the World Health Organization (WHO) 350,000 people a year are dying from Hepatitis C. Gilead Sciences and Bristol-Myers Squibb together developed a promising cure and HCV advocates are outraged at lack of its development

San Antonio, Texas (PRWEB) February 23, 2013

According to the World Health Organization, (WHO) 350,000 people die each year from Hepatitis C and it is the most widespread blood borne infection in the country. (http://www.who.int/mediacentre/factsheets/fs164/en/). The disease now kills more people than AIDS (http://www.reuters.com/article/2012/02/23/us-hepc-idUSTRE81M1HR20120223).

San Antonian, Margaret Dudley, was diagnosed with Hepatitis C in 2011. Dudley is leading a charge to make a cure available to the four million Americans living with the disease. “We feel Gilead Sciences has a moral responsibility to work with Bristol-Myers to put an end to this epidemic disease,” says Dudley.

She established the HCV Coalition for The Cure to raise awareness about Hepatitis C and the cure that exists. She says the greatest frustration is knowing that a treatment is available without toxic ribavirin and/or interferon, but it’s not being used. She says two pills from two different drug makers have shown remarkable results, but their use against Hepatitis C is stalled. Dudley says drug company Gilead Sciences has balked at further development with Bristol-Myers Squibb rather than moving forward with the medications they created together to cure the most common forms of Hepatitis C, which is a combination of Gilead Sciences’ sofosbuvir combined with Bristol’s daclatasvir (Bristol urges combo hepatitis C study with Gilead http://www.reuters.com/article/2012/05/31/us-bristolmyers-gilead-idUSBRE84U0WC20120531)

On February 19, 2013, Dudley, with the support of her husband, Gary Dudley, co-owner of San Antonio based corporation, SWBC, and a number of other advocates announced a drive to obtain a hundred thousand signatures, that would get the White House to help move things along.

“They can stop this disease by collaborating on this cure for a disease that’s reached epidemic proportions,” says 61 year old Dudley – a mother and grandmother.

The Hepatitis C virus resides in the liver. Over time, cysts and scar tissue form, causing liver cirrhosis. Tumors can develop and the liver can fail. This is the number one reason for liver transplants. “We feel very strongly with help of the nation and the White House, we can get these drug companies to come together with their previously proven treatment to cure the disease.”

“You have the cure, you developed it, give us access to it,” says Margaret directing her plea to the drug companies.

Dudley is urging everyone to go to http://www.hepc-cured.org and sign the White House petition.